Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ketamine · Ketalar

Small molecule · Antagonist of N-methyl-D-aspartate receptor · developed by Ph Health

Approved FDA, Feb 1970
4 Registered trials

What is Ketamine?

Ketamine is a racemic, non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. Its major metabolite, norketamine, has weaker activity at the same receptor.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ketalar
Drug type
Small molecule
Targets
N-methyl-D-aspartate receptor
Mechanism
Antagonist of N-methyl-D-aspartate receptor
Pathways
glutamatergic NMDA receptor signaling
Therapy area
Psychiatry
Developer
Ph Health
In trials of
ALKS, GRCE, ROIV, SUPN
FDA status
Approved as Ketalar (February 19, 1970), NDA016812 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Mar 27, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05907213 Phase 1 Pain, Postoperative Completed GRCE
NCT05049343 Phase 1 Healthy Volunteer Completed SUPN
NCT02611921 Phase 1 Autism Spectrum Disorder Completed ROIV
NCT04928703 Early Phase 1 Healthy Completed ALKS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Autism Spectrum DisorderDepression, PostpartumHealthyHealthy VolunteerPain, Postoperative

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.